Vancocin Generic In Vivo Testing Waiver Is Not Scientifically Sound, ViroPharma Says
This article was originally published in The Pink Sheet Daily
Executive Summary
More stringent testing is needed because the product treats two potentially life-threatening diseases, the firm argues in a supplement to its Petition for Stay of Action.
You may also be interested in...
ViroPharma Sets Legal Argument Against FDA Decision On Generic Vancocin
The firm, which markets vancomycin hydrochloride, says FDA decision on bioequivalence testing violates FOIA and other statutes.
Tarceva Pancreatic Cancer Indication Turned Down In The EU
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.
Teva To Investigate High-Dose Copaxone
A Phase III trial will compare 40 mg/day glatiramer to the 20 mg/day approved dose.